AstraZeneca Shares Fall Despite EPS Beat and Raised GuidanceAstraZeneca beat earnings-per-share (EPS) estimates and raised guidance, but shares still fell. Investors should watch for developments around the drug Enhertu.
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.
